目的:探究多发性肌炎(polymyositis,PM)相关肺间质病变(Interstitial lung disease,ILD)的具体发病机制及其临床诊治.方法:择取2011年1月至2016年1月期间由笔者所在医院收治的60例P M合并ILD患者,按照有无合并ILD进行分组:合并组:30例患者;非合并组:30例患者.对比两组患者在临床指标和临床表现上的异同点.结果:两组患者均有肺部症状明显者与无症状者,其中合并组肺部症状多为呼吸困难与干咳,且合并组中发热者与关节痛者例数更多.此外,合并组在羟丁酸脱氢酶、血清肌酸激酶、天冬氨酸转氨酶、乳酸脱氢酶、血沉以及抗体阳性率上均要远远高于非合并组,差异有统计学意义(P<0.05),其他指标如CRP等则差异无统计学意义(P>0.05).结论:PM合并ILD预后较差,临床表现不一,故应对其加强生化检测,进而采取针对措施诊治.%Objective:To explore the pathogenesis and clinical diagnosis and treatment of specific mat-ter lesions among polymyositis associated lung. Methods:Among the 60 patients who are dignosised Polymyo-sitis from January 2011 to January 2012 in our department,30 was the combination group and 30 was the not combination group according to the fact with the interstitial lung disease or not.The clinical indicators and man-ifestations between the two group were compared. Results:The patients without any symptom and with obvious lung symptoms are both found in the two groups.Among the combination group,the lung symptoms are mostly dyspnea and dry cough and the patients with fever or arthralgia are more.In addition,the Hydroxybutyrate De-hydrogenase(HBDH), serum creatine kinase(CK) , aspartate transaminase(AST), lactic dehydrogenase ( LDH) , erythrocyte sedimentation rate ( ESR) and the positive rate of anti-jo-1 antibody in the combination group are higher than the other group.There was significant difference(P<0.05).However,in the comparition of the other indictors,such as the C-reactive protein( CRP),there was no significant difference(P>0.05). Conclution:The patients who dignosised Polymyositis with Interstitial lung disease have the poor prognosis and have different clinical manifection. So, we should give them the biochemical tests frequently, then can take measures to make a dignosis and to give treatment.
展开▼
